Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) shot up 0.6% on Wednesday after Wells Fargo & Company raised their price target on the stock from $210.00 to $240.00. Wells Fargo & Company ...

Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ...

As Wall Street’s broader market averages continue to decline on Tuesday, following Monday’s significant sell-off, the idea of ...

For each stock, we provide details on the highest individual sale, the number of insider sales exceeding $10 million ...

Don't discount the power of momentum. Some studies have found that momentum trading -- buying stocks or exchange-traded funds ...

After two years in the shadows, health stocks are back as a haven for investors navigating economic uncertainty.

BeiGene aims to be a next-generation oncology innovator by broadening its drug and pipeline portfolio to various solid tumors in addition to blood cancers. As such, it been actively investing to build ...

Stock market investors have enjoyed strong annual returns over the past two years, but analysts caution that 2025 may not ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

AbbVie partners with Gubra in a $2.2 billion deal to develop GUB014295, an amylin analog for obesity. The move marks AbbVie's entry into the competitive weight-loss market.

Johnson & Johnson has rewarded shareholders with a quarterly dividend. As a Dividend King, it is the epitome of a steady and ...